Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1097/01.ju.0000030719.78258.4b | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
The impact of post-nephroureterectomy surgically induced chronic kidney disease on survival outcomes.
BJU Int
December 2024
Department of Urology, UC San Diego School of Medicine, La Jolla, California, USA.
Article Synopsis
- This study aimed to analyze how common surgically induced chronic kidney disease (CKD-S) is in patients with upper tract urothelial carcinoma (UTUC) after they undergo radical nephroureterectomy (RNU), focusing on survival outcomes.* -
- Researchers looked at data from 1,862 patients and found that 34.7% developed CKD-S3a and 39.6% developed CKD-S3b after surgery, with older age, lower preoperative kidney function, and certain chemotherapy treatments linked to higher risks of developing CKD-S3b.* -
- The study revealed that while CKD-S3b patients had worse overall survival rates (59% over 5 years), CK
Correction: Role of neoadjuvant chemotherapy in patients with locally advanced and clinically positive nodes Upper Tract Urothelial Carcinoma treated with Nephroureterectomy: real-world data from the ROBUUST 2.0 Registry.
World J Urol
November 2024
Department of Urology, IRCCS "Regina Elena" National Cancer Institute, Via Elio, Chianesi 53, Rome, Italy.
Role of neoadjuvant chemotherapy in patients with locally advanced and clinically positive nodes Upper Tract Urothelial Carcinoma treated with Nephroureterectomy: real-world data from the ROBUUST 2.0 Registry.
World J Urol
October 2024
Department of Urology, IRCCS "Regina Elena" National Cancer Institute, Via Elio, Chianesi 53, Rome, Italy.
Article Synopsis
- The study investigates the effects of neoadjuvant and adjuvant chemotherapy on survival rates in patients with Upper tract urothelial carcinoma undergoing Nephroureterectomy, using data from a multicenter registry.
- A total of 1,994 patients were analyzed, revealing that neoadjuvant chemotherapy notably improved cancer-specific and overall survival, especially in patients with advanced tumors or positive nodes.
- The results suggest a significant survival benefit from neoadjuvant chemotherapy, indicating a need for further research to explore its impact in this patient population.
The Diabetes Technology Society Error Grid and Trend Accuracy Matrix for Glucose Monitors.
J Diabetes Sci Technol
November 2024
University of California San Francisco, San Francisco, CA, USA.
Article Synopsis
- An error grid is a tool that helps compare glucose levels measured by devices to see if they are correct and to identify any risks.
- Experts created a new error grid called the DTS Error Grid that works for both blood glucose monitors (BGMs) and continuous glucose monitors (CGMs), organizing accuracy into five risk zones.
- The results showed that the DTS Error Grid provides a clearer picture of how accurate these devices are and includes a separate matrix to evaluate how well CGMs track glucose trends over time.
Adjuvant Pembrolizumab versus Observation in Muscle-Invasive Urothelial Carcinoma.
N Engl J Med
January 2025
From the Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda (A.B.A., N.S., S.N., L.L., L.C.), the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore (J.H.-C.), and the Investigational Drug Branch, Cancer Therapy Evaluation Program, National Cancer Institute, National Institutes of Health, Rockville (H.S., E.S.) - all in Maryland; the Alliance Statistics and Data Management Center, Mayo Clinic, Rochester, MN (K.V.B., M.O., C.M., G.P.B.); AdventHealth Cancer Institute and the University of Central Florida, Orlando (G.S.); Dana-Farber/Harvard Cancer Center, Boston (S.B., B.M.); UNC Lineberger Comprehensive Cancer Center, Chapel Hill (W.Y.K.), and Duke University Medical Center and Duke Cancer Institute, Durham (J.H., S.H.) - both in North Carolina; the University of Kansas Cancer Center, Westwood (R.P.); Memorial Sloan Kettering Cancer Center, New York (M.Y.T., M.J.M., J.E.R.), and Roswell Park Comprehensive Cancer Center, Buffalo (G.C.) - both in New York; the University of Chicago Comprehensive Cancer Center, Chicago (R.F.S., C.W., Y.W., O.H.), and Loyola University Medical Center, Maywood (M.W.) - both in Illinois; the Alliance Protocol Operations Office, University of Chicago, Chicago (C.W., Y.W., O.H.); Fox Chase Cancer Center, Philadelphia (D.M.G.); Fred Hutchinson Cancer Center and the University of Washington, Seattle (P.G.); Rogel Cancer Center, University of Michigan, Ann Arbor (Z.R.R.); Yale Cancer Center, Yale School of Medicine, New Haven, CT (J.W.K., D.P.); Winship Cancer Institute, Emory University, Atlanta (M.A.B.); Mayo Clinic Comprehensive Cancer Center, Phoenix, AZ (P.S.); Oklahoma University Health Stephenson Cancer Center, Oklahoma City (A. Tripathi); University of Texas Southwestern Medical Center, Dallas (S.C.); Stanford University, Stanford (S.S.), and Kaiser Permanente Riverside Medical Center, Riverside (H.M.) - both in California; and Vanderbilt-Ingram Cancer Center, Nashville (A. Tan).
Background: Muscle-invasive urothelial carcinoma is an aggressive disease with high rates of relapse. Whether pembrolizumab as adjuvant therapy would be effective in patients with high-risk muscle-invasive urothelial carcinoma after radical surgery is unknown.
Methods: In this phase 3 trial, we randomly assigned patients, in a 1:1 ratio, to receive pembrolizumab at a dose of 200 mg every 3 weeks for 1 year or to undergo observation.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!